Voyager Therapeutics, Inc. VYGR
Set alert
1.74 USD +0.02 +1.16%
As of Nov 2, 11:57 AM ET
1.71 Day range 1.80
1.68 52-week range 5.48
- YTD
- -55.73%
- 1 year
- -62.74%
- Open
- 1.74
- Prev close
- 1.72
- Mkt cap
- 106.91M
- Vol
- 559.17K
- Avg vol
- 661.94K
- EPS
- -1.81
- P/E
- 0.00
- Div yield
- 0.00%
More statistics
- Low
- 1.71
- High
- 1.80
- Forward P/E
- -3.41
- Beta
- 0.89
- Short ratio
- 4.44
- Inst. own
- 65.52%
- Dividend
- 0.00
- Ex-div date
- 50-d avg
- 6.52
- 200-d avg
- 7.56
- 1y target
- 17.10
2Y chart
Events in this range
- Nov 12, 2024Earnings: -0.16; estimate -0.45; surprise 64.44%
- Nov 14, 2024Rating: HC Wainwright & Co. · Buy → Buy
- Nov 14, 2024Rating: Canaccord Genuity · Buy → Buy
- Dec 2, 2024Rating: Citigroup · — → Buy
Signals (113)
| Name | Date | Ago |
|---|---|---|
| MACD: Buy Signal | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 30, 2026 | 3 days ago |
| RSI: Oversold | Oct 22, 2026 | 1 week ago |
| RSI: Oversold | Sep 25, 2026 | 1 month ago |
| SMA: Bearish | Sep 9, 2026 | 1 month ago |
| MACD: Sell Signal | Sep 9, 2026 | 1 month ago |
| SMA: Bullish | Aug 21, 2026 | 2 months ago |
| SMA: Bearish | Aug 20, 2026 | 2 months ago |
| SMA: Bullish | Aug 19, 2026 | 2 months ago |
| MACD: Buy Signal | Aug 4, 2026 | 3 months ago |
| MACD: Sell Signal | Jul 13, 2026 | 3 months ago |
| SMA: Bearish | Jul 9, 2026 | 3 months ago |
| SMA: Bullish | Jul 7, 2026 | 3 months ago |
| SMA: Bearish | Jul 6, 2026 | 3 months ago |
| SMA: Bullish | Jul 2, 2026 | 4 months ago |
| MACD: Buy Signal | Jun 16, 2026 | 4 months ago |
| MACD: Sell Signal | Jun 2, 2026 | 5 months ago |
| SMA: Bearish | May 28, 2026 | 5 months ago |
| MACD: Buy Signal | May 28, 2026 | 5 months ago |
| SMA: Bullish | May 27, 2026 | 5 months ago |
| MACD: Sell Signal | May 18, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bearish | May 15, 2026 | 5 months ago |
| SMA: Bullish | May 8, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bearish | May 7, 2026 | 5 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| SMA: Bullish | May 6, 2026 | 6 months ago |
| MACD: Buy Signal | May 6, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| SMA: Bearish | Apr 24, 2026 | 6 months ago |
| MACD: Sell Signal | Apr 24, 2026 | 6 months ago |
| SMA: Bullish | Apr 17, 2026 | 6 months ago |
| SMA: Bearish | Apr 16, 2026 | 6 months ago |
| MACD: Buy Signal | Apr 16, 2026 | 6 months ago |
| SMA: Bullish | Apr 15, 2026 | 6 months ago |
| SMA: Bullish | Apr 14, 2026 | 6 months ago |
| SMA: Bearish | Apr 10, 2026 | 6 months ago |
| SMA: Bullish | Apr 9, 2026 | 6 months ago |
| SMA: Bearish | Apr 8, 2026 | 6 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| SMA: Bullish | Apr 1, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| SMA: Bearish | Mar 30, 2026 | 7 months ago |
| SMA: Bullish | Mar 25, 2026 | 7 months ago |
| SMA: Bearish | Mar 18, 2026 | 7 months ago |
| MACD: Sell Signal | Mar 18, 2026 | 7 months ago |
| SMA: Bearish | Mar 17, 2026 | 7 months ago |
| RSI: Overbought | Mar 10, 2026 | 7 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| SMA: Bullish | Feb 25, 2026 | 8 months ago |
| MACD: Buy Signal | Feb 24, 2026 | 8 months ago |
| SMA: Bearish | Feb 4, 2026 | 9 months ago |
| MACD: Sell Signal | Feb 4, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 23, 2026 | 9 months ago |
| SMA: Bullish | Jan 22, 2026 | 9 months ago |
| SMA: Bearish | Jan 16, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 15, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 14, 2026 | 9 months ago |
| MACD: Sell Signal | Jan 12, 2026 | 9 months ago |
| MACD: Buy Signal | Jan 8, 2026 | 9 months ago |
| MACD: Sell Signal | Dec 19, 2025 | 10 months ago |
| MACD: Buy Signal | Dec 3, 2025 | 11 months ago |
| SMA: Bearish | Nov 4, 2025 | 12 months ago |
| MACD: Sell Signal | Oct 17, 2025 | 1 year ago |
| RSI: Overbought | Oct 8, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 29, 2025 | 1 year ago |
| MACD: Sell Signal | Sep 23, 2025 | 1 year ago |
| SMA: Bullish | Sep 10, 2025 | 1 year ago |
| SMA: Bearish | Sep 9, 2025 | 1 year ago |
| SMA: Bullish | Sep 5, 2025 | 1 year ago |
| RSI: Overbought | Sep 5, 2025 | 1 year ago |
| MACD: Buy Signal | Sep 3, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 22, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 13, 2025 | 1 year ago |
| SMA: Bullish | Aug 12, 2025 | 1 year ago |
| SMA: Bearish | Aug 8, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 8, 2025 | 1 year ago |
| MACD: Buy Signal | Aug 6, 2025 | 1 year ago |
| SMA: Bullish | Aug 4, 2025 | 1 year ago |
| MACD: Sell Signal | Aug 1, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 30, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 29, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 28, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 25, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 24, 2025 | 1 year ago |
| SMA: Bullish | Jul 23, 2025 | 1 year ago |
| SMA: Bearish | Jul 21, 2025 | 1 year ago |
| MACD: Sell Signal | Jul 21, 2025 | 1 year ago |
| SMA: Bullish | Jul 16, 2025 | 1 year ago |
| SMA: Bearish | Jul 15, 2025 | 1 year ago |
| SMA: Bullish | Jul 9, 2025 | 1 year ago |
| MACD: Buy Signal | Jul 2, 2025 | 1 year ago |
| MACD: Sell Signal | Jun 18, 2025 | 1 year ago |
| SMA: Bearish | Jun 17, 2025 | 1 year ago |
| SMA: Bullish | Jun 4, 2025 | 1 year ago |
| MACD: Buy Signal | Jun 3, 2025 | 1 year ago |
| MACD: Sell Signal | May 22, 2025 | 1 year ago |
| MACD: Buy Signal | May 19, 2025 | 1 year ago |
| MACD: Sell Signal | May 13, 2025 | 1 year ago |
| MACD: Buy Signal | Apr 14, 2025 | 1 year ago |
| RSI: Oversold | Apr 3, 2025 | 1 year ago |
| MACD: Sell Signal | Mar 31, 2025 | 1 year ago |
| RSI: Oversold | Mar 31, 2025 | 1 year ago |
| MACD: Buy Signal | Mar 5, 2025 | 1 year ago |
| RSI: Oversold | Mar 3, 2025 | 1 year ago |
| RSI: Oversold | Feb 21, 2025 | 1 year ago |
| RSI: Oversold | Feb 14, 2025 | 1 year ago |
| MACD: Sell Signal | Feb 11, 2025 | 1 year ago |
| RSI: Oversold | Feb 11, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 23, 2025 | 1 year ago |
| MACD: Sell Signal | Jan 10, 2025 | 1 year ago |
| MACD: Buy Signal | Jan 3, 2025 | 1 year ago |
Key statistics
- Market cap
- 313.00M
- Enterprise value
- 14.08M
- Trailing P/E
- 8.68
- Forward P/E
- -3.41
- PEG ratio
- 0.00
- Price / sales
- 1.91
- Price / book
- 0.95
- EPS (TTM)
- 0.66
- Beta
- 0.89
- Dividend yield
- 0.00%
- Payout ratio
- 0.00%
- Profit margin
- 15.80%
- Revenue (TTM)
- 163.78M
- Revenue growth
- 433.80%
- Free cash flow
- -19.75M
- Total cash
- 345.36M
- Total debt
- 45.35M
- Return on equity
- 10.22%
- Shares outstanding
- 54.63M
- Short % of float
- 5.58%
- 50-day average
- 6.52
- 200-day average
- 7.56
Analyst view
Consensus: none
Price target (mean) 17.10 +882.8% upside
Now 1.74
- Target (low)
- 11.00
- Target (mean)
- 17.10
- Target (high)
- 30.00
Ratings (0m) 10 10 buy · 0 hold · 0 sell
- Strong buy1
- Buy9
- Hold0
- Sell0
- Strong sell0
Next earnings
Consensus EPS estimate -0.34035.
Financials — quick view
VYGR Revenue — quarterly 3.17M
VYGR Net income — quarterly -24.47M
VYGR EPS — quarterly -0.40
Earnings
| Report date | Quarter ending | EPS estimate | EPS reported | Surprise | Surprise % |
|---|---|---|---|---|---|
| Nov 12, 2024 | Sep 1, 2024 | -0.45 | -0.16 | +0.29 | +64.44% |
| Aug 6, 2024 | Jun 1, 2024 | -0.38 | -0.18 | +0.20 | +52.63% |
| May 13, 2024 | Mar 1, 2024 | -0.44 | -0.20 | +0.24 | +54.55% |
| Feb 28, 2024 | Dec 1, 2023 | -0.59 | 1.25 | +1.84 | +311.86% |
| Nov 6, 2023 | Sep 1, 2023 | -0.58 | -0.59 | -0.01 | -1.72% |
| Aug 3, 2023 | Jun 1, 2023 | -0.59 | -0.51 | +0.08 | +13.56% |
Upgrades / downgrades
| Date | Firm | Action | From | To |
|---|---|---|---|---|
| Dec 2, 2024 | Citigroup | init | — | Buy |
| Nov 14, 2024 | Canaccord Genuity | main | Buy | Buy |
| Nov 14, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 24, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
| Oct 16, 2024 | Leerink Partners | init | — | Outperform |
| Aug 20, 2024 | HC Wainwright & Co. | reit | Buy | Buy |
About Voyager Therapeutics, Inc.
Voyager Therapeutics, Inc., a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial. In addition, the company develops VY-FXN01, which is in preclinical trial to treat friedreich's ataxia; and GBA1 gene replacement to treat parkinson's disease and is in preclinical trial. Further, it provides research program for the treatment of Huntington's disease. The company has collaboration and license agreements with Alexion; AstraZeneca Rare Disease; Novartis Pharma AG; Neurocrine Biosciences, Inc; and Sangamo Therapeutics, Inc. Voyager Therapeutics, Inc. was incorporated in 2013 and is headquartered in Lexington, Massachusetts.
- Sector
- Healthcare
- Industry
- Biotechnology
- Country
- United States
- Website
- voyagertherapeutics.com
News
- Voyager's Tau-Targeted Gene Therapy VY1706 and Anti-Tau Antibody VY7523 for Alzheimer's Disease to Be Featured in Poster Presentations at CTAD 2026
- Voyager: Maintaining A Strong Buy For Q4 PET Imaging Data AD And More
- Voyager Therapeutics Appoints Robin Swartz As President, Effective October 20, And Is Expected To Become CEO In Q1 2027
- Voyager Announces CEO Succession Plan, Appoints Robin Swartz President
- Voyager Therapeutics (NASDAQ:VYGR) Share Price Breaks Below 50 Day Moving Average – Here’s What Happened
- Tonix Pharmaceuticals (NASDAQ:TNXP) and Voyager Therapeutics (NASDAQ:VYGR) Critical Review
- Aligos Therapeutics (NASDAQ:ALGS) & Voyager Therapeutics (NASDAQ:VYGR) Head-To-Head Analysis
- Voyager Therapeutics, Inc. (VYGR) Presents at Wells Fargo 21st Annual Healthcare Conference Transcript
- BlackRock Inc. Takes $18.10 Million Position in Voyager Therapeutics, Inc. $VYGR
- Voyager to Present at Upcoming Investor Conferences
Your note
Sign in to keep a note on VYGR — it syncs with the Stock Master app.
Insider holders
| Insider | Relation | Latest transaction | Date | Shares held |
|---|---|---|---|---|
| CARTER TODD ALFRED | Officer | Sale | Feb 20, 2024 | 87,627 |
| FAHEY SANDELL JACQUELYN | Officer | Sale | Oct 1, 2024 | 86,001 |
| FERGUSON TOBY | Officer | Stock Award(Grant) | Mar 31, 2024 | 105,000 |
| HESSLEIN ROBERT W | General Counsel | Sale | Mar 19, 2023 | 102,200 |
| JORGENSEN NATHAN D. | Chief Financial Officer | Stock Award(Grant) | Sep 30, 2024 | 80,000 |
| NEUROCRINE BIOSCIENCE INC | Beneficial Owner of more than 10% of a Class of Security | Purchase | Feb 22, 2023 | 8,575,320 |
Institution ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Blackrock Inc. | 9.94% | 5,430,430 | 31.12M | Sep 29, 2024 |
| Armistice Capital, LLC | 9.52% | 5,200,000 | 29.80M | Sep 29, 2024 |
| EcoR1 Capital, LLC | 7.17% | 3,917,546 | 22.45M | Sep 29, 2024 |
| Vanguard Group Inc | 5.83% | 3,186,427 | 18.26M | Sep 29, 2024 |
| Farallon Capital Management LLC | 4.20% | 2,292,000 | 13.13M | Sep 29, 2024 |
| Dimensional Fund Advisors LP | 2.02% | 1,105,044 | 6.33M | Sep 29, 2024 |
Fund ownership
| Holder | % held | Shares | Value | Reported |
|---|---|---|---|---|
| Vanguard Total Stock Market Index Fund | 3.14% | 1,713,895 | 9.82M | Sep 29, 2024 |
| iShares Russell 2000 ETF | 2.21% | 1,206,285 | 6.91M | Oct 30, 2024 |
| Vanguard Extended Market Index Fund | 1.18% | 646,396 | 3.70M | Sep 29, 2024 |
| Price (T.Rowe) Health Sciences Fund | 1.14% | 622,401 | 3.57M | Sep 29, 2024 |
| Fidelity Small Cap Index Fund | 0.86% | 469,640 | 2.69M | Aug 30, 2024 |
| Vanguard Explorer Fund, Inc. | 0.84% | 457,063 | 2.62M | Jul 30, 2024 |